https://scholars.lib.ntu.edu.tw/handle/123456789/548855
標題: | An asian multicenter clinical trial to assess the efficacy and tolerability of acarbose compared with placebo in type 2 diabetic patients previously treated with diet | 作者: | Chan J.C.N. KIN-WEI CHAN Ho L.L.T. Fuh M.M.C. Horn L.C. Sheaves R. Panelo A.A. Kim D.-K. Embong M. |
公開日期: | 1998 | 出版社: | American Diabetes Association Inc. | 卷: | 21 | 期: | 7 | 起(迄)頁: | 1058-1061 | 來源出版物: | Diabetes Care | 摘要: | OBJECTIVE- To assess the efficacy, safety, and tolerability of acarbose versus placebo during a 24-week treatment period in Asian type 2 diabetic patients with dietary failure. RESEARCH DESIGN AND METHODS- After a 6-week screening period, 126 multiethnic Asian type 2 diabetic patients (64 men, 62 women; mean age ± SD, 53.4 ± 10 years) were randomized to receive acarbose (n = 63) or placebo (n = 63). The dosage was increased from 50 mg t.i.d. at week 0 to 100 mg t.i.d. at week 4. Patients were then followed up at weeks 10, 16, and 24. At each visit, body weight, blood pressure, and metabolic indexes were measured. At weeks 0 and 24, fasting plasma glucose and insulin were measured before and 1 h after the administration of an individually tailored breakfast. RESULTS- Using the intention-to-treat analysis, there were greater reductions in (mean [95% CI]) HbA(1c) (-0.70 [-1.00 to -0.39] vs. -0.27% [-0.54 to 0];P = 0.04), fasting plasma glucose (-0.37 [-0.75 to 0.02] vs. 0.41 mmol/l [-0.08 to 0.90]; P = 0.017) and 1-h plasma glucose (- 0.77 [-1.44 to -0.10] vs. 0.65 mmol/l [-0.07 to 1.36]; P = 0.05) in the acarbose group compared with the placebo group. With acarbose treatment, 78% of patients achieved an HbA(1c) <8% compared with 56% in the placebo group (P = 0.003). There was a greater reduction in body weight (-1.31 [-2.46 to - 0.15] vs. 0.16 kg [-3.36 to 0.10]; P = 0.02) and higher incidence of flatulence (56 vs. 37%; P = 0.032) in the acarbose than in the placebo group. Using baseline HbA(1c) and race as covariates, there were no significant inter-ethnic differences in treatment responses (P = 0.232 for treatment- race interaction; P < 0.001 for treatment effect). The dropout rates were similar between the two groups (acarbose, 11 of 63; placebo, 6 of 63). There were no significant laboratory adverse events in either group. CONCLUSIONS- In this multicenter study involving six ethnic groups, acarbose 100 mg t.i.d. was an effective, safe, and generally well-tolerated therapy in Asian type 2 diabetic patients with dietary failure. In some patients with troublesome gastrointestinal symptoms, a lower dosage may be necessary. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-0031847292&doi=10.2337%2fdiacare.21.7.1058&partnerID=40&md5=518f00e3f57c7af1218a1e86377f5379 https://scholars.lib.ntu.edu.tw/handle/123456789/548855 |
ISSN: | 0149-5992 | DOI: | 10.2337/diacare.21.7.1058 | SDG/關鍵字: | acarbose; glibenclamide; metformin; sulfonylurea; abdominal distension; adult; article; Asian; clinical trial; controlled clinical trial; controlled study; diabetic diet; diarrhea; drug efficacy; drug safety; drug tolerability; female; flatulence; human; major clinical study; male; multicenter study; non insulin dependent diabetes mellitus; randomized controlled trial; treatment indication; treatment outcome |
顯示於: | 腫瘤醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。